CD Antigens
CD Antigens(CD抗原)
Cell surface antigens of leukocytes are called CD antigens, and important for immune reactions of organisms. As lymphocytes mature, they express different protein receptors on the cell surface, which can aid in determining the type and maturation stage of the cells being examined. These proteins or antigen markers are called Clusters of Differentiation
The term CD means a cluster of differentiation OR a cluster of determinants which indicates the lineage or maturational stage of lymphocytes. During the course of development from precursor cells into functionally mature forms, lymphocytes display a complex pattern of surface antigens, some of which are acquired at certain stages while others are lost.
These surface antigens were identified initially by monoclonal antibodies and the designations of the antibodies were used often as synonyms for the cell surface proteins they detected, giving rise to a plethora of different names. CD antigens are present on some subpopulations and functional types of leukocytes. CD antigens participate in immune reaction as receptors for cell communication (e.g. adherence molecules, antigen recognizing receptors).
CD antigen nomenclature describes different monoclonal antibodies from different sources that recognize identical antigens. Numbers are assigned arbitrarily. A small letter w before the number designation stands for "workshop". It indicates that the CD designation is tentative.
CD antigens are found on practically all known cell types. In some cases CD antigens are expressed only at certain stages of development or under certain conditions, for example after cell activation or in certain disease conditions. In Hematology the morphological criteria is for the description of specific developmental stages of lymphocytes unlike in CD antigens which the use of monoclonal antibodies allows the objective and precise analysis and standardized typing of mature and immature normal and malignant cells of all hematopoietic cell lineages. The use antibodies also helps to delineate the biologic traits that distinguish normal immune and hematopoietic cells from their malignant counterparts, which is utmost important in the understanding of hematological malignancies.
The expression of CD antigens is influenced by cytokines, such as binding of ligands to CD antigens which has shown to modulate the expression of cytokines. CD antigens have been shown to be identical with receptors of cytokines such as CD25 (TAC antigen).
CD antigens appear to carry out cytokine receptor-like functions such as CD27, CD30 and CD40. CD antigens are involved in modulating the biological activities of cytokines such as CD4, CD28 and CD40. CD antigens exist also in soluble forms for example CD14, CD21, CD23, CD27, CD100 and CD137.
The CD Antigen’s designation isn’t related to the biological function, thus CD antigens include receptors, glycans, adhesion molecules, membrane-bound enzymes, etc.
The most commonly know CD antigens are CD4 and CD8 which are markers for T-helper and T-suppressor cells, respectively. CD4 binds to relatively invariant sites on class II major histocompatibility complex molecules outside the peptide-binding groove, which interacts with the T-cell receptor. CD4 is also the central docking receptor for human immunodeficiency virus. CD8 binds to relatively invariant sites on class I major histocompatibility complex molecules outside the peptide-binding groove. CD8 is also expressed on a subset of dendritic cells. Other more important CD antigens include the leukocytes integrins (CD11/CD18) and the hematopoietic stem cell marker CD34.
CD69 is homologous to members of a supergene family of type II integral membrane proteins having C-type lectin domains. Although the precise functions of the CD-69 antigen is not known, evidence suggests that these proteins transmit mitogenic signals across the plasma membrane and are up- regulated in response to lymphocyte activation
In the last decade the wide palette of monoclonal antibodies has been prepared which recognise of CD antigens on human cells. Much less monoclonal antibodies are available specific for typing of domestic animal cells. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI).
- CD1(4)
- CD14(5)
- CD164(2)
- CD2(5)
- CD200(5)
- CD204(2)
- CD207(2)
- CD226(2)
- CD23(2)
- CD244(2)
- CD247(2)
- CD27(3)
- CD274(3)
- CD3(28)
- CD300(4)
- CD33(2)
- CD34(3)
- CD36(2)
- CD4(5)
- CD40(2)
- CD46(2)
- CD47(7)
- CD5(2)
- CD55(2)
- CD58(2)
- CD5L(3)
- CD68(3)
- CD7(2)
- CD73(12)
- CD74(2)
- CD79(3)
- CD80(1)
- CD84(2)
- CD8B(2)
- CD93(2)
- CD99(2)
- Fc Fragment of IgG Receptor(6)
- Other CD Antigens(46)
- sCD40L(5)
- LAG-3(3)
- Mucin(4)
- CD38(2)
- CD19(1)
CD Antigens 相关产品(200)
- GC74494GresonitamabCAS: 2413817-97-5纯度: >99.00%
Gresonitamab(AMG 910)是一种半衰期延长(HLE)双特异性T细胞接合剂(BiTE)抗体,靶向CD3阳性T细胞和CLDN18.2表达的肿瘤细胞。
- GC74497TepoditamabCAS: 2044679-53-8纯度: >92.00%
Tepoditamab (MCLA-117)是一种双特异性单克隆抗体,可结合骨髓细胞的clecl12a和细胞毒性T细胞的CD3。
- GC74498TeclistamabCAS: 2119595-80-9纯度: >99.00%
Teclistamab是一种针对BCMA和CD3的人双特异性抗体,其识别靶细胞上的BCMA和T细胞上的CD3,并诱导T细胞介导的细胞毒性,导致T细胞活化和随后的靶细胞裂解。
- GC74524VoxalatamabCAS: 2411871-58-2纯度: >99.00%
Voxalatamab(JNJ-63898081)是一种结合PSMA和CD3的双特异性IgG4抗体,具有抗癌活性,用于癌症研究。
- GC74525VibecotamabCAS: 2138442-13-2纯度: >99.00%
Vibecotamab (XmAb14045)是一种有效的针对CD123和CD3的双特异性抗体,可刺激T细胞介导的靶向杀伤表达CD123的细胞。
- GC74526VepsitamabCAS: 2413453-53-7纯度: >98.00%
Vepsitamab(AMG 199)是一种抗MUC17/CD3 BiTE抗体,与T细胞上的CD3和肿瘤细胞上表达的MUC17结合,介导重定向的肿瘤细胞裂解,并诱导T细胞活化和增殖。
- GC74531CatumaxomabCAS: 509077-98-9纯度: >98.00%
Catumaxomab是一种三功能IgG2抗体,由小鼠和大鼠的重链和轻链组成,与人EpCAM和人CD3受体结合。
- GC74545FavezelimabCAS: 2231068-83-8纯度: >97.00%
Favezelimab (MK-4280)是一种人源化抗LAG-3单克隆抗体,可阻断LAG-3与其配体MHC II类之间的相互作用。
- GC74548FlotetuzumabCAS: 1664355-28-5纯度: >98.00%
Flotetuzumab(MGD006;S80880)是一种正在研究的CD123/CD3双特异性双亲和力再靶向抗体(DART)分子。
- GC74581Modakafusp alfaCAS: 2254522-19-3纯度: >96.00%
Modakafusp alfa (TAK-573)是一种人源化的抗cd38 IgG4单克隆抗体,与2个减毒的IFNα2b分子融合,将干扰素- α传递到表达cd38的细胞。
- GC74589OntorpaceptCAS: 2131089-46-6纯度: >99.00%
Ontorpacept (TTI-621)是一种可溶性融合蛋白,由与人IgG1 Fc区连接的人SIRPα n端(1-118)组成。
- GC74591PacanalotamabCAS: 2251756-52-0纯度: >97.00%
Pacanalotamab (amg 420;BI-836909)是一种靶向BCMA和CD3E的双特异性t细胞接合剂(BiTE)。
- GC74593PasotuxizumabCAS: 1442657-12-6纯度: >98.00%
Pasotuxizumab (BAY 2010112)是一种PSMA和CD3双特异性t细胞接合器(BiTE)。
- GC74604LinvoseltamabCAS: 2408319-25-3纯度: >99.00%
Linvoseltamab是一种针对BCMA (TNFRSF17)和CD3 epsilon的双特异性抗体。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC74494 | Gresonitamab | 2413817-97-5 | >99.00% | |
Gresonitamab(AMG 910)是一种半衰期延长(HLE)双特异性T细胞接合剂(BiTE)抗体,靶向CD3阳性T细胞和CLDN18.2表达的肿瘤细胞。 | ||||
| GC74497 | Tepoditamab | 2044679-53-8 | >92.00% | |
Tepoditamab (MCLA-117)是一种双特异性单克隆抗体,可结合骨髓细胞的clecl12a和细胞毒性T细胞的CD3。 | ||||
| GC74498 | Teclistamab | 2119595-80-9 | >99.00% | |
Teclistamab是一种针对BCMA和CD3的人双特异性抗体,其识别靶细胞上的BCMA和T细胞上的CD3,并诱导T细胞介导的细胞毒性,导致T细胞活化和随后的靶细胞裂解。 | ||||
| GC74524 | Voxalatamab | 2411871-58-2 | >99.00% | |
Voxalatamab(JNJ-63898081)是一种结合PSMA和CD3的双特异性IgG4抗体,具有抗癌活性,用于癌症研究。 | ||||
| GC74525 | Vibecotamab | 2138442-13-2 | >99.00% | |
Vibecotamab (XmAb14045)是一种有效的针对CD123和CD3的双特异性抗体,可刺激T细胞介导的靶向杀伤表达CD123的细胞。 | ||||
| GC74526 | Vepsitamab | 2413453-53-7 | >98.00% | |
Vepsitamab(AMG 199)是一种抗MUC17/CD3 BiTE抗体,与T细胞上的CD3和肿瘤细胞上表达的MUC17结合,介导重定向的肿瘤细胞裂解,并诱导T细胞活化和增殖。 | ||||
| GC74528 | Urabrelimab | 2249722-58-3 | >98.00% | |
Urabrelimab(SRF231)是一种阻断CD47-SIRP相互作用的全人源性抗CD47单克隆抗体。 | ||||
| GC74530 | Ubamatamab | 2305629-50-7 | >99.00% | |
Ubamatamab(REGN4018)是一种针对粘蛋白16(MUC16)和CD3的人源化双特异性抗体。 | ||||
| GC74531 | Catumaxomab | 509077-98-9 | >98.00% | |
Catumaxomab是一种三功能IgG2抗体,由小鼠和大鼠的重链和轻链组成,与人EpCAM和人CD3受体结合。 | ||||
| GC74539 | Solitomab | 1005198-65-1 | >98.00% | |
Solitomab(AMG 110)是一种双特异性抗CD3和抗上皮细胞粘附分子(EpCAM)抗体。 | ||||
| GC74545 | Favezelimab | 2231068-83-8 | >97.00% | |
Favezelimab (MK-4280)是一种人源化抗LAG-3单克隆抗体,可阻断LAG-3与其配体MHC II类之间的相互作用。 | ||||
| GC74546 | Fianlimab | 2126132-98-5 | >99.00% | |
Fianlimab(REGN3767)是一种针对T细胞上的免疫检查点受体LAG-3的人单克隆抗体,具有抗肿瘤活性。 | ||||
| GC74548 | Flotetuzumab | 1664355-28-5 | >98.00% | |
Flotetuzumab(MGD006;S80880)是一种正在研究的CD123/CD3双特异性双亲和力再靶向抗体(DART)分子。 | ||||
| GC74571 | Ligufalimab | 2428381-55-7 | >98.00% | |
Ligufalimab(AK 117)是一种人源化IgG4抗CD47单克隆抗体。 | ||||
| GC74576 | Mezagitamab | 2227490-52-8 | >99.00% | |
Mezagitamab(TAK-079)是一种IgG1λ抗CD38单克隆抗体。 | ||||
| GC74581 | Modakafusp alfa | 2254522-19-3 | >96.00% | |
Modakafusp alfa (TAK-573)是一种人源化的抗cd38 IgG4单克隆抗体,与2个减毒的IFNα2b分子融合,将干扰素- α传递到表达cd38的细胞。 | ||||
| GC74582 | Nivatrotamab | - | >99.00% | |
Nivatrotamab (Hu3F8-BsAb)是人源抗gd2 /CD3双特异性抗体。 | ||||
| GC74585 | Obexelimab | 1690307-05-1 | >95.00% | |
Obexelimab(XmAb5871)是一种人源化抗CD19抗体。 | ||||
| GC74586 | Obrindatamab | 2069959-72-2 | >99.00% | |
Obrindatamab是一种人源化抗B7-H3/CD3双特异性抗体。 | ||||
| GC74588 | Plamotamab | 2138442-31-4 | >99.00% | |
Plamotamab(XmAb-13676)是一种结合CD3和CD20的人双特异性抗体(bsAb)。 | ||||
| GC74589 | Ontorpacept | 2131089-46-6 | >99.00% | |
Ontorpacept (TTI-621)是一种可溶性融合蛋白,由与人IgG1 Fc区连接的人SIRPα n端(1-118)组成。 | ||||
| GC74591 | Pacanalotamab | 2251756-52-0 | >97.00% | |
Pacanalotamab (amg 420;BI-836909)是一种靶向BCMA和CD3E的双特异性t细胞接合剂(BiTE)。 | ||||
| GC74593 | Pasotuxizumab | 1442657-12-6 | >98.00% | |
Pasotuxizumab (BAY 2010112)是一种PSMA和CD3双特异性t细胞接合器(BiTE)。 | ||||
| GC74604 | Linvoseltamab | 2408319-25-3 | >99.00% | |
Linvoseltamab是一种针对BCMA (TNFRSF17)和CD3 epsilon的双特异性抗体。 | ||||
